Asset sale offer provides solution for liquidity issues and maturing debt Voting support agreements in favour of the transaction have been entered into with various Shareholders ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback